Literature DB >> 19528501

Breast tumor cells transendothelial migration induces endothelial cell anoikis through extracellular matrix degradation.

Nicole Peyri1, Madeleine Berard, Françoise Fauvel-Lafeve, Veronique Trochon, Brigitte Arbeille, He Lu, Chantal Legrand, Michel Crepin.   

Abstract

Mutual interactions between human breast cancer cells and endothelial cells were studied in a model mimicking tumor cell intravasation. MDA-MB-231 tumor cells and human umbilical vein endothelial cells (HUVEC) were cocultured on opposite sides of a Transwell filter allowing tumor cell contacts with the basement membrane of the HUVEC forming endothelium and tumor cell transendothelial migration. Confocal microscopy analysis showed that transmigrating MDA-MB-231 cells lay under the HUVEC, thereby inducing HUVEC detachment and tumor cell-HUVEC contact-dependent apoptosis. GM6001 a matrix metalloproteinase (MMP) inhibitor inhibited almost completely, the MDA-MB-231 cell transendothelial migration and the anoikis process. In this intravasation model, a tumor cell invasive mechanism was demonstrated (i) induction of extensive endothelial anoikis induced by degradation of the extracellular matrix (ECM) components, (ii) activation of pro-matrix metalloproteinase (MMP)-2 into MMP-2 by the MT1-MMP-TIMP (tissue inhibitor metalloproteinase) 2-pro-MMP-2 membrane complex and (iii) attraction and migration of metastatic cell through apoptotic endothelium. These interactions could partly explain the necrosis-angiogenesis relationship in tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528501

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow.

Authors:  Shankar J Evani; Rajesh G Prabhu; V Gnanaruban; Ender A Finol; Anand K Ramasubramanian
Journal:  FASEB J       Date:  2013-04-24       Impact factor: 5.191

Review 2.  Epithelial-to-mesenchymal transitions and circulating tumor cells.

Authors:  Arnaud Bonnomet; Anne Brysse; Anthony Tachsidis; Mark Waltham; Erik W Thompson; Myriam Polette; Christine Gilles
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-07       Impact factor: 2.673

3.  A microfluidic platform for modeling metastatic cancer cell matrix invasion.

Authors:  Laura Blaha; Chentian Zhang; Mario Cabodi; Joyce Y Wong
Journal:  Biofabrication       Date:  2017-09-01       Impact factor: 9.954

4.  Engineering a Novel 3D Printed Vascularized Tissue Model for Investigating Breast Cancer Metastasis to Bone.

Authors:  Haitao Cui; Timothy Esworthy; Xuan Zhou; Sung Yun Hann; Robert I Glazer; Rong Li; Lijie Grace Zhang
Journal:  Adv Healthc Mater       Date:  2019-12-17       Impact factor: 9.933

5.  Oleic acid promotes MMP-9 secretion and invasion in breast cancer cells.

Authors:  Adriana Soto-Guzman; Napoleon Navarro-Tito; Luis Castro-Sanchez; Raul Martinez-Orozco; Eduardo Perez Salazar
Journal:  Clin Exp Metastasis       Date:  2010-07-09       Impact factor: 5.150

Review 6.  A New Antitumor Direction: Tumor-Specific Endothelial Cells.

Authors:  Jing Liang; Shouqi Wang; Guowei Zhang; Baoyu He; Qingli Bie; Bin Zhang
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

7.  Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins.

Authors:  Jun Xu; Steve Seung-Young Lee; Howon Seo; Liang Pang; Yearin Jun; Ruo-Yu Zhang; Zhong-Yin Zhang; Pilhan Kim; Wooin Lee; Stephen J Kron; Yoon Yeo
Journal:  Small       Date:  2018-11-09       Impact factor: 13.281

8.  In vitro vascularized tumor platform for modeling tumor-vasculature interactions of inflammatory breast cancer.

Authors:  Manasa Gadde; Caleb Phillips; Neda Ghousifam; Anna G Sorace; Enoch Wong; Savitri Krishnamurthy; Anum Syed; Omar Rahal; Thomas E Yankeelov; Wendy A Woodward; Marissa N Rylander
Journal:  Biotechnol Bioeng       Date:  2020-07-21       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.